Dr. Dorothy J. Park, MD

Dr. Park practices at Cedars-Sinai Medical Center in West Hollywood, California.

Dr. Park's NPI, 1083610596, was assigned on June 21, 2005. Dr. Park graduated from David Geffen School of Medicine at UCLA in 1987. Dr. Park holds California license G64946.

Dr. Park's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, West Hollywood, CA 90048 in Los Angeles County. The practice phone is (323) 866-8600.

Dr. Park's primary practice is Cedars-Sinai Medical Center in West Hollywood, California. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Park to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Park practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Park's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Park is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, lung cancer, lymphoma, neutropenia and purpura and thrombocytopenia among the conditions Dr. Park treats.

CMS data shows 969 Medicare services from Dr. Park across 7 procedure codes in 2024, for 279 Medicare patients. Medicare paid $52,915 for them. Every service was in an office.

CMS counts 279 Medicare patients who saw Dr. Park in 2024. The largest group is 65 to 74, with 123 patients. 75% of them have cancer, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Park's median patient age at 71, with 95% women.

In 2024, Dr. Park wrote 900 Medicare Part D claims for 197 patients. 83% of them were for generic drugs. CMS names the drug for 697 of them, across 18 drugs with 11 or more claims each, at $1,407,457 in total drug cost. In 2023, CMS named 833 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Park for performance year 2024, reported as part of a group.

Dmand AI links 26 papers to Dr. Park, published from 2001 to 2016. 2001 was the busiest year, with 2. The most frequent topics are Tumor Cells, Cultured, Cell Differentiation and RNA, Messenger. Dr. Park has published most often in Blood. Dr. Park's most frequent co-authors are Harold Phillip Koeffler, MD, Norihiko Kawamata, MD and Scott C. Kogan, MD.

Dmand AI links Dr. Park to 5 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Brain Neoplasms and Breast Neoplasms, Male.

CMS Open Payments shows 64 general payments to Dr. Park from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Bristol-Myers Squibb Company paid the most, $557.

Dmand AI lists 1 award for Dr. Park, most recently CMS Stage 1 EHR in 2013.

Dr. Park graduated from David Geffen School of Medicine at UCLA in 1987. Dr. Park is a member of ACP and ASCO.

Dr. Park is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.